Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL286061 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL395235 | 1.00 | — | — | |
| SCHEMBL195234 | 0.97 | — | — | |
| SCHEMBL1201325 | 0.97 | — | — | |
| SCHEMBL429737 | 0.97 | — | — | |
| Dimethylamine SCHEMBL28140801 | 0.86 | — | — | |
| Cyclohexylamine SCHEMBL28843654 | 0.84 | ALDH1A1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL2224224 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL4789691 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL2226080 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118284073-A | Wide-bandgap perovskite solar cell and preparation method thereof | 四川大学 | 2024-07-02 | — | — | CN | claimed |
| CN-117647598-A | High performance liquid analysis method for enantiomer of (S) -3-amino tetrahydrofuran and intermediate | 上海司太立制药有限公司 | 2024-03-05 | — | — | CN | claimed |
| WO-2020046403-A1 | NOVEL PROCESS FOR THE PREPARATION OF ENANTIOPURE 3- ENANTIOPURE 3-AMINO TETRAHYDROFURAN AND ITS SALTS | MAJEED MUHAMMED (US) | 2020-03-05 | — | — | WO | claimed |
| US-10421734-B1 | Process for the preparation of enantiopure 3-amino tetrahydrofuran and its salts | SAMI LABS LIMITED (IN) | 2019-09-24 | — | — | US | claimed |
| CN-102391214-A | Synthetic method of (S)-3-amino tetrahydrofuran hydrochloride | ZHEJIANG QIMING BIOCHEMICAL TECHNOLOGY CO LTD | 2012-03-28 | — | — | CN | claimed |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719603-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| WO-2002020024-A1 | PURINE RIBOSIDES AS ANTIARRHYTHMICS | CV THERAPEUTICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002018380-A1 | 7-OXO PYRIDOPYRIMIDINES AS INHIBITORS OF A CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| EP-1081155-A2 | N6 heterocyclic substituted adenosine derivatives | CV THERAPEUTICS, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-0992510-A1 | N6 heterocyclic substituted adenosine derivatives | CV THERAPEUTICS, INC. (US) | 2000-04-12 | — | — | EP | disclosed |
| CN-1234803-A | N heterocyclic substituted adenosine derivatives | CV THERAPEUTICS INC (US) | 1999-11-10 | — | — | CN | disclosed |
| EP-0920438-A2 | N6 HETEROCYCLIC SUBSTITUTED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5789416-A | CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS | CV THERAPEUTICS (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1998008855-A2 | N6 HETEROCYCLIC SUBSTITUTED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 1998-03-05 | — | — | WO | disclosed |